Apple v Masimo
US Judge Rules Against Apple In Masimo Pulse Oximeter Patent Case
Apple smartwatches could face an import ban after a U.S. judge ruled that the company infringed on one of Masimo's pulse oximeter patents.
Apple to halt some Apple Watch Sales in US
Apple is planning to stop selling some versions of the Apple Watch in the United States as soon as this week to get ahead of what could be one of the most momentous patent disputes in years.
Biden administration upholds Apple Watch ban
US president Joe Biden's administration on Tuesday opted not to veto a government tribunal's ruling to ban imports of Apple Watches.
Apple files emergency motion against Apple Watch ban
Apple filed an emergency motion with a U.S. appeals court to pause a ban on importing and selling some of its Apple Watch models.
U.S. Appeals Court temporarily stops Apple Watch Sales Ban
Apple will be able to sell the latest Apple Watches after an import ban was temporarily stopped by a U.S. appeals court on Wednesday.
Apple Resumes Watch Series 9 and Ultra 2 Sales in U.S.
Apple has started resuming sales of its Apple Watch Series 9 and Ultra 2 in the country.
Apple to Remove Blood-Oxygen Tool From Apple Watches
Apple is planning to remove its blood-oxygen feature from the Apple Watch Series 9 and Apple Watch Ultra 2, to circumvent a US ban of the devices.
Apple Watches Banned again in U.S.
From Jan. 18, Apple will again be banned from selling Apple Watch Series 9 and Ultra 2 devices in the US due to its ongoing patent infringement case with Masimo.
Apple iOS 18.6.1 restores blood oxygen monitoring in the United States
Apple has released iOS 18.6.1 for U.S. iPhones only, bringing a Blood Oxygen monitoring update.
Apple watchOS 11.6.1 restores blood oxygen monitoring in the United States
Apple has released watchOS 11.6.1 in tandem with iOS 18.6.1 bringing a Blood Oxygen monitoring update in the United States.
Masimo sues US Customs over Apple Watch Blood Oxygen feature
Masimo has filed a lawsuit against U.S. Customs and Border Protection (CBP) over the reactivation of the Apple Watch’s Blood Oxygen feature.
US Customs asks court to dismiss Masimo case
Masimo recently filed a lawsuit against U.S. Customs and Border Protection, accusing the agency of improperly allowing Apple to resume selling Apple Watches with the Blood Oxygen feature activated.
US Jury orders Apple to pay Masimo $634M in never ending patent fight
A federal jury in California has found that Apple infringed on a Masimo patent for its pulse oximetry technology and awarded Masimo $634 million in damages.
Apple Watch Blood Oxygen Workaround Doesn’t Infringe on Masimo Patents
U.S. International Trade Commission (ITC) judge has determined that Apple’s current methods of leveraging blood oxygen sensing on Apple Watch do not infringe on Masimo’s patents
Apple is planning to remove its blood-oxygen feature from the Apple Watch Series 9 and Apple Watch Ultra 2, to circumvent a US ban of the devices if an appeal of the decision fails.
The plan was disclosed Monday by Masimo, which has been locked in a feud with Apple over patents related to the technology. It said that US Customs and Border Protection approved the move on Jan. 12.
The agency “decided that Apple’s redesign falls outside the scope” of an import ban by the US International Trade Commission (ITC), signaling that the adjustment will let Apple keep its watches on the market.
The ITC had ruled in October that Apple’s devices violated Masimo patents related to blood-oxygen measurement. That led Apple to pause sales of the smartwatches just ahead of Christmas, though an interim stay allowed the company to bring the products back late last month.
Apple developed a software workaround intended to sidestep the dispute and presented the solution last week to the customs agency, which is in charge of enforcing import bans. Apple explained that the redesigned watches “definitively” do not contain the technology at issue, known as pulse oximetry, according to Masimo.
The dramatic step would probably only take place if Apple fails to win a longer stay from a federal appeals court. The company said Monday it expects the US Court of Appeals for the Federal Circuit to rule on its motion for a stay for the entire appeal period as early as Tuesday. The company said it believes the period could last a year or more.
